New Chapter in the PCSK9 Book: Oral Inhibition of PCSK9 Binding to the LDL Receptor With a Macrocyclic Peptide.

HomeCirculationVol. 148, No. 2New Chapter in the PCSK9 Book: Oral Inhibition of PCSK9 Binding to the LDL Receptor With a Macrocyclic Peptide No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextNew Chapter in the PCSK9 Book: Oral Inhibition of PCSK9 Binding to the LDL Receptor With a Macrocyclic Peptide Ulf Landmesser and Umidakhon Makhmudova Ulf LandmesserUlf Landmesser Correspondence to: Ulf Landmesser, MD, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany. Email E-mail Address: [email protected] https://orcid.org/0000-0002-0214-3203 Department of Cardiology, Angiology, and Intensive Medicine, Deutsches Herzzentrum der Charité, Berlin, Germany (U.L., U.M.). Friede Springer Cardiovascular Prevention Center at Charité, Berlin, Germany (U.L., U.M.). DZHK (German Centre for Cardiovascular Research), partner site Berlin, Germany (U.L.). Berlin Institute of Health, Germany (U.L.). Search for more papers by this author and Umidakhon MakhmudovaUmidakhon Makhmudova https://orcid.org/0000-0001-8746-5465 Department of Cardiology, Angiology, and Intensive Medicine, Deutsches Herzzentrum der Charité, Berlin, Germany (U.L., U.M.). Friede Springer Cardiovascular Prevention Center at Charité, Berlin, Germany (U.L., U.M.). Search for more papers by this author Originally published10 Jul 2023https://doi.org/10.1161/CIRCULATIONAHA.123.065407Circulation. 2023;148:159–161This article is a commentary on the followingOrally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein ReceptorFootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Disclosures, see page 161.Circulation is available at www.ahajournals.org/journal/circCorrespondence to: Ulf Landmesser, MD, Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany. Email ulf.landmesser@charite.deReferences1. Abifadel M, Varret M, Rabès J-P, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.Nat Genet. 2003; 34:154–156. doi: 10.1038/ng1161CrossrefMedlineGoogle Scholar2. Rosenson RS, Hegele RA, Fazio S, Cannon CP. The evolving future of PCSK9 inhibitors.J Am Coll Cardiol. 2018; 72:314–329. doi: 10.1016/j.jacc.2018.04.054CrossrefMedlineGoogle Scholar3. Horton J, Cohen J, Hobbs H. Molecular biology of PCSK9: its role in LDL metabolism.Trends Biochem Sci. 2007; 32:71–77. doi: 10.1016/j.tibs.2006.12.008CrossrefMedlineGoogle Scholar4. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, et al; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.N Engl J Med. 2015; 372:1489–1499. doi: 10.1056/NEJMoa1501031CrossrefMedlineGoogle Scholar5. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, et al; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.N Engl J Med. 2014; 370:1809–1819. doi: 10.1056/NEJMoa1316222CrossrefMedlineGoogle Scholar6. Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, Bisch JA, Richardson T, Jaros M, Wijngaard PLJ, et al; ORION-10 and ORION-11 Investigators. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol.N Engl J Med. 2020; 382:1507–1519. doi: 10.1056/NEJMoa1912387CrossrefMedlineGoogle Scholar7. Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall T, Troquay RPT, Turner T, Visseren FLJ, et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol.N Engl J Med. 2017; 376:1430–1440. doi: 10.1056/NEJMoa1615758CrossrefMedlineGoogle Scholar8. Wang W, Khojasteh SC, Su D. Biosynthetic strategies for macrocyclic peptides.Molecules. 2021; 26:3338. doi: 10.3390/molecules26113338CrossrefMedlineGoogle Scholar9. Tombling BJ, Zhang Y, Huang Y-H, Craik DJ, Wang CK. The emerging landscape of peptide-based inhibitors of PCSK9.Atherosclerosis. 2021; 330:52–60. doi: 10.1016/j.atherosclerosis.2021.06.903CrossrefMedlineGoogle Scholar10. Alleyne C, Amin RP, Bhatt B, Bianchi E, Blain JC, Boyer N, Branca D, Embrey MW, Ha SN, Jette K, et al. Series of novel and highly potent cyclic peptide PCSK9 inhibitors derived from an mRNA display screen and optimized via structure-based design.J Med Chem. 2020; 63:13796–13824. doi: 10.1021/acs.jmedchem.0c01084CrossrefMedlineGoogle Scholar11. Johns DG, Campeau L-C, Banka P, Bautmans A, Bueters T, Bianchi E, Branca D, Bulger PG, Crevecoeur I, Ding F-X, et al. Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor.Circulation. 2023; 148:144–158. doi: 10.1161/CIRCULATIONAHA.122.063372LinkGoogle Scholar12. Tucker TJ, Embrey MW, Alleyne C, Amin RP, Bass A, Bhatt B, Bianchi E, Branca D, Bueters T, Buist N, et al. A series of novel, highly potent, and orally bioavailable next-generation tricyclic peptide PCSK9 inhibitors.J Med Chem. 2021; 64:16770–16800. doi: 10.1021/acs.jmedchem.1c01599CrossrefMedlineGoogle Scholar13. Tyagi M, Begnini F, Poongavanam V, Doak BC, Kihlberg J. Drug syntheses beyond the rule of 5.Chem Eur J. 2020; 26:49–88. doi: 10.1002/chem.201902716CrossrefMedlineGoogle Scholar14. Ballantyne CM, Banka P, Mendez G, Garcia R, Rosenstock J, Rodgers A, Mendizabal G, Mitchel Y, Catapano AL. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616.J Am Coll Cardiol. 2023; 81:1553–1564. doi: 10.1016/j.jacc.2023.02.018CrossrefMedlineGoogle Scholar15. Brandts J, Ray KK. Novel and future lipid-modulating therapies for the prevention of cardiovascular disease [published online April 13, 2023].Nat Rev Cardiol. doi: 10.1038/s41569-023-00860-8. https://nature.com/articles/s41569-023-00860-8CrossrefGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesOrally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein ReceptorDouglas G. Johns, et al. Circulation. 2023;148:144-158 July 11, 2023Vol 148, Issue 2 Advertisement Article InformationMetrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.123.065407PMID: 37428833 Originally publishedJuly 10, 2023 KeywordsPCSK9EditorialsPCKS9 oral inhibitionLDL cholesterolPDF download Advertisement SubjectsLipids and Cholesterol